Q3 2022

Filed Nov 14, 2022 · 10-Q · 45 days after period end · 0001654954-22-015303

Q3 2022 · 10-Q

Revenue—

Net Income

-$3.44M

N/M vs Q3 2021

EPS, diluted—

Operating Income-$3,417,216N/M

Operating Cash Flowderived-$3,246,830N/M

Same quarter

Metric	Q3 2022	Q3 2021	Q3 2020	Q3 2019
Revenue	—	—	—	$0.00
Net Income	-$3.44M	-$2.66M	-$3.26M	-$3.41M
EPS Diluted	—	-$0.06	-$0.15	-$0.46

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR